facebook_pixel
Options Strategy 10 October 2013
BLUE PHOENIX FINANCIALS PREMIUM CONTENT Not a member? Join Now!
Gilead Sciences Nov $65 Calls: Buy To Profit From Idelalisib & Sofosbuvir

Gilead Sciences Nov $65 Calls: Buy To Profit From Idelalisib & Sofosbuvir

* NOTE: The Following Call Options Buy Strategy Is ONLY For Investors Who Can Afford Short Term Price Risk & Volatility * Gilead Sciences Inc., the world’s largest biotechnology company by market value, gained the most in five months after patients benefited enough from the cancer drug idelalisib to end a late-stage study early * […]

FIND OUT MORE